Replimune Group (NASDAQ:REPL) Stock Price Up 6.1% - Still a Buy?

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) was up 6.1% during mid-day trading on Thursday . The stock traded as high as $14.72 and last traded at $14.63. Approximately 565,284 shares traded hands during trading, a decline of 23% from the average daily volume of 734,544 shares. The stock had previously closed at $13.78.

Analyst Ratings Changes

Several equities analysts recently issued reports on REPL shares. Jefferies Financial Group boosted their price target on shares of Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday, December 4th. HC Wainwright boosted their price target on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Finally, BMO Capital Markets boosted their price target on shares of Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $19.29.

Replimune Group Price Performance

The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The firm's 50 day moving average is $12.68 and its 200 day moving average is $11.87. The firm has a market cap of $1.08 billion, a P/E ratio of -4.55 and a beta of 1.30.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). As a group, analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Insider Transactions at Replimune Group

In other news, CEO Sushil Patel sold 10,000 shares of the company's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the transaction, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 8.80% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Sterling Capital Management LLC lifted its position in Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after purchasing an additional 1,655 shares during the period. Tower Research Capital LLC TRC lifted its position in Replimune Group by 696.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after purchasing an additional 5,922 shares during the period. Aster Capital Management DIFC Ltd lifted its position in Replimune Group by 8,798.9% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after purchasing an additional 8,183 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Replimune Group during the fourth quarter valued at approximately $117,000. Finally, Quantinno Capital Management LP bought a new position in Replimune Group during the fourth quarter valued at approximately $127,000. Institutional investors own 92.53% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.